Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexrazoxane (ICRF-187)

G Weiss1, M Loyevsky, V R Gordeuk

  • 1Department of Internal Medicine, University Hospital, Innsbruck, Austria. guenter.weiss@uibk.ac.at

General Pharmacology
|January 15, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distribution of DMT 1 within the human glandular system.

Histology and histopathology·2003
Same author

Atorvastatin suppresses interferon-gamma -induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines.

Clinical and experimental immunology·2003
Same author

Assessing menstrual cycles with urinary hormone assays.

American journal of physiology. Endocrinology and metabolism·2002
Same author

The Koebner phenomenon: review of the literature.

Journal of the European Academy of Dermatology and Venereology : JEADV·2002
Same author

Oral terbinafine in the treatment of onychomycosis: a comparison of continuous and extended-pause regimens.

Journal of the European Academy of Dermatology and Venereology : JEADV·2002
Same author

Long-term sequelae of HFE deletion in C57BL/6 x 129/O1a mice, an animal model for hereditary haemochromatosis.

European journal of clinical investigation·2002
Same journal

Endothelium-dependent vasorelaxant and antiproliferative effects of apigenin.

General pharmacology·2002
Same journal

Reversal of hypercapnia induces endothelin-dependent constriction of basilar artery in rabbits with acute metabolic alkalosis.

General pharmacology·2002
Same journal

Reversal of hypercapnia induces KATP channel and NO-independent constriction of basilar artery in rabbits with acute metabolic alkalosis.

General pharmacology·2002
Same journal

Contractile responses in spontaneously diabetic mice. II. Effect of cholestyramine on enhanced contractile response of aorta to norepinephrine in C57BL/KsJ (db/db) mice.

General pharmacology·2002
Same journal

Contractile responses in spontaneously diabetic mice. I. Involvement of superoxide anion in enhanced contractile response of aorta to norepinephrine in C57BL/KsJ(db/db) mice.

General pharmacology·2002
Same journal

Investigation of basal endothelial function in the obese Zucker rat in vitro.

General pharmacology·2002
See all related articles

Dexrazoxane is a cardioprotective drug used in cancer chemotherapy. It prevents heart damage by chelating iron and inhibiting topoisomerase II, suggesting potential in other diseases.

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Dexrazoxane (ICRF-187) is the sole approved drug for preventing anthracycline-induced cardiotoxicity in cancer patients.
  • Its cardioprotective mechanism involves iron chelation from anthracycline complexes, thereby reducing harmful free radical formation.

Purpose of the Study:

  • To review the established cardioprotective role of dexrazoxane.
  • To explore the potential of dexrazoxane in novel therapeutic applications based on its broader biological effects.

Main Methods:

  • Literature review of dexrazoxane's pharmacological actions and clinical applications.
  • Analysis of its mechanisms, including iron chelation and topoisomerase II inhibition.

Main Results:

Related Experiment Videos

  • Dexrazoxane effectively prevents anthracycline-mediated cardiotoxicity.
  • The drug's ability to modulate topoisomerase II activity and cellular iron homeostasis is a key finding.

Conclusions:

  • Dexrazoxane's cardioprotective effects are well-documented in cancer chemotherapy.
  • Its influence on topoisomerase II and iron metabolism suggests promising future applications in cancer therapy, immunology, and infectious diseases.